- Home
- ZNTL vs OXSQ Comparison
ZNTL vs OXSQ Comparison
Compare ZNTL & OXSQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ZNTL | OXSQ |
|---|---|---|
| Founded | 2014 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 156.7M | 151.9M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | ZNTL | OXSQ |
|---|---|---|
| Price | $2.67 | $1.68 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $6.60 | N/A |
| AVG Volume (30 Days) | 557.3K | ★ 1.4M |
| Earning Date | 05-13-2026 | 03-03-2026 |
| Dividend Yield | N/A | ★ 25.00% |
| EPS Growth | ★ 47.87 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $67,425,000.00 | N/A |
| Revenue This Year | N/A | $3.61 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.01 | $1.56 |
| 52 Week High | $3.95 | $2.64 |
Technical Indicators
Market Signals| Indicator | ZNTL | OXSQ |
|---|---|---|
| Relative Strength Index (RSI) | 53.40 | 37.60 |
| Support Level | $1.29 | $1.68 |
| Resistance Level | $2.69 | $1.95 |
| Average True Range (ATR) | 0.21 | 0.04 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 32.46 | 14.79 |
Price Performance
Historical ComparisonAbout ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
About OXSQ Oxford Square Capital Corp.
Oxford Square Capital Corp is a closed-end, non-diversified management investment company with a focus is to seek an attractive risk-adjusted total return by investing in corporate debt securities and collateralized loan obligation (CLO) structured finance investments that own corporate debt securities. its capital is generally used by its corporate borrowers to finance organic growth, acquisitions, recapitalizations, and working capital. The group invests in various industries such as Structured Finance, IT Consulting, Business Services, Utilities, Software, Healthcare, Telecommunication Services, Plastics Manufacturing and Diversified Insurance.